
Opinion|Videos|May 28, 2025
Current Challenges in the Management of Bronchiectasis
Panelists discuss how the heterogeneity of bronchiectasis requires precise phenotyping and a treatable traits approach to address varying symptom profiles, from cough-predominant to shortness of breath–predominant presentations.
Advertisement
Episodes in this series

Clinical Brief: Challenges in Managing Heterogeneous Bronchiectasis Presentations
Main Discussion Topics
- Bronchiectasis presents heterogeneously in symptoms, etiology, and severity.
- Treatment approaches should be tailored to specific phenotypes.
- Different symptom presentations require different management priorities.
Key Points for Physicians
- Recognize common symptom phenotypes:
- Cough predominant: focus on airway clearance techniques
- Dyspnea predominant with minimal cough: emphasize exercise, nutrition, and pulmonary rehabilitation
- Frequent exacerbator: targeted antibiotic strategies and infection prevention
- Perform thorough diagnostic workup to identify underlying etiologies.
- Treat comorbidities such as reflux, aspiration, and sinus disease.
- Apply a “treatable traits” approach focusing on specific characteristics rather than using a one-size-fits-all strategy.
Notable Insights
The heterogeneity of bronchiectasis necessitates precision medicine approaches tailored to individual patient presentations rather than standardized treatment algorithms.
Clinical Significance
Recognizing and addressing the varied presentations of bronchiectasis through phenotype-specific approaches improves management outcomes and patient quality of life.
Advertisement
Related to this article

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.

Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.

Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.

Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.

The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
3
Preparing Practices for the Next Era of Hepatitis B Care
4
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
5

